Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma

Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma

Head and neck squamous cell carcinoma (HNSCC) is often diagnosed at an advanced stage and has a dismal prognosis. Nearly 10 years after the approval of cetuximab, anti-PD1/PD-L1 checkpoint inhibitors are the first drugs that have shown any survival benefit for the treatment on platinum-refractory re...

Full description

Bibliographic Details
Main Authors: Valerie Cristina, Ruth Gabriela Herrera-Gómez, Petr Szturz, Vittoria Espeli, Marco Siano
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:International Journal of Molecular Sciences
Subjects:
head and neck cancer
immunotherapy
combination treatment
Online Access:https://www.mdpi.com/1422-0067/20/21/5399

Similar Items

Similar Items